Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents

The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–...

Full description

Bibliographic Details
Main Authors: Adriane Halik, Christopher Maximilian Arends, Lars Bullinger, Frederik Damm, Mareike Frick
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/7/1689
_version_ 1797440107977900032
author Adriane Halik
Christopher Maximilian Arends
Lars Bullinger
Frederik Damm
Mareike Frick
author_facet Adriane Halik
Christopher Maximilian Arends
Lars Bullinger
Frederik Damm
Mareike Frick
author_sort Adriane Halik
collection DOAJ
description The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.
first_indexed 2024-03-09T12:03:22Z
format Article
id doaj.art-10905d6c19f64d9582a4f9673b554ff3
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-09T12:03:22Z
publishDate 2022-03-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-10905d6c19f64d9582a4f9673b554ff32023-11-30T23:00:38ZengMDPI AGCancers2072-66942022-03-01147168910.3390/cancers14071689Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsAdriane Halik0Christopher Maximilian Arends1Lars Bullinger2Frederik Damm3Mareike Frick4Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyThe number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.https://www.mdpi.com/2072-6694/14/7/1689AMLmutationsFLT3IDH1/2venetoclaxgemtuzumabozogamicin
spellingShingle Adriane Halik
Christopher Maximilian Arends
Lars Bullinger
Frederik Damm
Mareike Frick
Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
Cancers
AML
mutations
FLT3
IDH1/2
venetoclax
gemtuzumabozogamicin
title Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
title_full Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
title_fullStr Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
title_full_unstemmed Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
title_short Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
title_sort refining aml treatment the role of genetics in response and resistance evaluation to new agents
topic AML
mutations
FLT3
IDH1/2
venetoclax
gemtuzumabozogamicin
url https://www.mdpi.com/2072-6694/14/7/1689
work_keys_str_mv AT adrianehalik refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents
AT christophermaximilianarends refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents
AT larsbullinger refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents
AT frederikdamm refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents
AT mareikefrick refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents